For oral inhalation only. The capsule should be placed in a suitable inhaler device (e.g., Rotahaler, Revolizer) and the contents inhaled through the mouth. Do not swallow the capsule. Rinse mouth with water after use to prevent oral candidiasis.

Fluticasone Propionate is a synthetic trifluorinated corticosteroid that possesses potent anti-inflammatory activity. It acts by binding to glucocorticoid receptors in the airways, inhibiting the release of inflammatory mediators (e.g., cytokines, chemokines, eicosanoids) and reducing the activity of inflammatory cells (e.g., eosinophils, mast cells, lymphocytes). This reduces airway hyperresponsiveness and improves lung function.

• •Acute bronchospasm or status asthmaticus (Fluticasone is not a rescue inhaler)
• •Known hypersensitivity to fluticasone propionate or any component of the formulation.
• •Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.

Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

Acute overdose is unlikely to cause severe problems due to low systemic absorption. However, chronic overdose may lead to systemic corticosteroid effects like adrenal suppression. Treatment is supportive.

Pregnancy Category C. Use only if the potential benefit justifies the potential risk to the fetus. It is not known whether fluticasone propionate is excreted in human milk; use with caution in nursing mothers.